{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:38:02Z","timestamp":1790613482102,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remission. Current techniques for MRD assessment involve bone marrow (BM) aspirate sampling, which is invasive, subject to sample variability and is limited by spatial heterogeneity. We compared the performance of a non-invasive, circulating tumor DNA (ctDNA)-based MRD assay with multiparameter flow cytometry (MFC) of marrow aspirate to predict relapse in AHCT recipients with MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MRD assessment using ctDNA was retrospectively analyzed on 80 plasma samples collected at different time points from 28 patients, post-AHCT. MFC was used to assess MRD from BM biopsy. Individual archived BM aspirate slides or formalin-fixed paraffin-embedded slides from the time of MM diagnosis and matched blood were used\u00a0to assess MRD at 3 months, post-AHCT, using a personalized, tumor-informed ctDNA assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ctDNA was detectable in 70.8% (17\/24) of pre-AHCT patients and 53.6% (15\/28) of post-AHCT patients (3-month time point). Of the 15 post-AHCT ctDNA-positive patients, 14 relapsed on follow-up. The median PFS for ctDNA-positive patients was 31 months, and that for ctDNA-negative patients was 84 months (HR: 5.6; 95%CI: 1.8-17;p=0.0003). No significant difference in PFS was observed in patients stratified by MFC-based MRD status (HR 1.2; 95%CI: 0.3-3.4;p=0.73). The positive predictive value for ctDNA was also significantly higher than MFC (93.3% vs. 68.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrates tumor-informed ctDNA analysis is strongly predictive of MM relapse.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.786451","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T13:26:31Z","timestamp":1643808391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse"],"prefix":"10.3389","volume":"12","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Balcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Shchegrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Billings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran N.","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Van De Donk","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple Myeloma, Version 2.2016","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients With Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD Profiling Defines Outcome and Unveils Different Modes of Treatment Resistance in Standard-and High-Risk Myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial Genomic Heterogeneity in Multiple Myeloma Revealed by Multi-Region Sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating Tumor DNA and Liquid Biopsy in Oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trsl.2018.05.003","article-title":"Novel Biomarkers in Multiple Myeloma","volume":"201","author":"Levin","year":"2018","journal-title":"Trans Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.03.001","article-title":"Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival","volume":"16","author":"Dhakal","year":"2016","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD Status in Relation to Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients: A Meta-Analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of Next-Generation Sequencing (NGS) and Next-Generation Flow (NGF) for Minimal Residual Disease (MRD) Assessment in Multiple Myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B13","first-page":"38","article-title":"Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma","volume-title":"Seminars in Hematology","author":"Pugh","year":"2018"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood Monitoring of Circulating Tumor Plasma Cells by Next Generation Flow in Multiple Myeloma After Therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow-Based Flow Cytometry for Tracking Measurable Residual Disease in Patients With Multiple Myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.02.003","article-title":"Minimal Residual Disease in Multiple Myeloma: Defining the Role of Next Generation Sequencing and Flow Cytometry in Routine Diagnostic Use","volume":"53","author":"Maclachlan","year":"2021","journal-title":"Pathology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by Deep Sequencing From Circulating Tumor DNA Does Not Correlate With Results Obtained in the Bone Marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3608","article-title":"Minimal Residual Disease by Circulating Tumor DNA Analysis for Colorectal Cancer Patients Receiving Radical Surgery: An Initial Report From CIRCULATE-Japan","volume":"39","author":"Yukami","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.786451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T13:26:34Z","timestamp":1643808394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.786451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":20,"alternative-id":["10.3389\/fonc.2022.786451"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.786451","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"article-number":"786451"}}